Microfluidic-Based Holonomic Constraints of siRNA in the Kernel of Lipid/Polymer Hybrid Nanoassemblies for Improving Stable and Safe In Vivo Delivery
Source abstract
Abstract
A safe and efficient delivery system is critical for clinical application of siRNA. However, the conventional electrostatic interaction-based siRNA nanoplexes with bulk mixing preparation were always unsatisfactory for its stability and safety. In this study, the new core-shell lipid/PCL-PEI/siRNA nanoparticles (LPS NPs) endowing holonomic constraint of siRNA in the inner core were prepared by microfluidic technology. On the microfluidic chip, siRNAs were completely compressed into the inner hydrophilic core of reverse PCL-PEI micelles at a low N/P ratio of 5, followed by coating a neutral lipid membrane to form core-shell nanoparticles, which had a uniform size (120.2 ± 1.4 nm) and a negative charge (-8.8 ± 1.6 mV). Compared to bulk mixing-based LMS NPs, the lower usage of cationic PCL-PEI materials and stronger protection of siRNA in serum were found in the microfluidic-based LPS NPs. Furthermore, it was demonstrated that the LPS NPs exhibited significant downregulation of EGFR mRNA and protein expression level both in vitro and in vivo, and showed significant inhibition of tumor growth following systemic administration along with no obvious systemic toxicity. These findings demonstrated that the microfluidic-based lipid/polymer hybrid nanoassemblies would offer a promising siRNA delivery system for clinical application.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanopore and Nanochannel Transport Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China
School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, China
Funding
Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China
References (60)
Show source-provided references
1. 10.1016/j.addr.2007.03.00510.1016/j.addr.2007.03.005 ↗
2. 10.1128/MMBR.67.4.657-685.200310.1128/MMBR.67.4.657-685.2003 ↗
3. 10.1038/nature0895610.1038/nature08956 ↗
4. 10.1038/3588810.1038/35888 ↗
5. 10.1016/j.ejps.2010.03.01910.1016/j.ejps.2010.03.019 ↗
6. 10.1126/scitranslmed.300836210.1126/scitranslmed.3008362 ↗
7. 10.1038/mt.2009.9110.1038/mt.2009.91 ↗
8. 10.1021/acsnano.6b0719510.1021/acsnano.6b07195 ↗
9. 10.1021/acsnano.6b0385810.1021/acsnano.6b03858 ↗
10. 10.1016/j.biomaterials.2014.03.01210.1016/j.biomaterials.2014.03.012 ↗
11. 10.1038/nmat318710.1038/nmat3187 ↗
12. 10.1073/pnas.070783110410.1073/pnas.0707831104 ↗
13. 10.1016/j.jconrel.2006.04.01410.1016/j.jconrel.2006.04.014 ↗
14. 10.1016/j.biomaterials.2011.07.04710.1016/j.biomaterials.2011.07.047 ↗
15. 10.1021/nn304406610.1021/nn3044066 ↗
16. 10.1002/adfm.20120221510.1002/adfm.201202215 ↗
17. 10.1021/nn301164a10.1021/nn301164a ↗
18. 10.1002/adma.20170328510.1002/adma.201703285 ↗
19. 10.1016/j.biomaterials.2013.11.04610.1016/j.biomaterials.2013.11.046 ↗
20. 10.1039/C6NR04034A10.1039/C6NR04034A ↗
21. 10.1038/nnano.2012.16810.1038/nnano.2012.168 ↗
22. 10.1016/j.nantod.2016.10.00610.1016/j.nantod.2016.10.006 ↗
23. 10.1016/j.addr.2017.08.00310.1016/j.addr.2017.08.003 ↗
24. 10.1038/nature0505810.1038/nature05058 ↗
25. 10.1021/nl801736q10.1021/nl801736q ↗
26. 10.1021/nn901433u10.1021/nn901433u ↗
27. 10.1021/ja050443910.1021/ja0504439 ↗
28. 10.1088/1361-6528/aa6d1510.1088/1361-6528/aa6d15 ↗
29. 10.1038/mtna.2012.2810.1038/mtna.2012.28 ↗
30. 10.1021/acs.biomac.7b0085110.1021/acs.biomac.7b00851 ↗
31. 10.1021/acsnano.5b0579210.1021/acsnano.5b05792 ↗
32. 10.1016/j.jconrel.2011.07.03510.1016/j.jconrel.2011.07.035 ↗
33. 10.1021/acs.nanolett.8b0068110.1021/acs.nanolett.8b00681 ↗
34. 10.1016/j.coche.2014.12.00110.1016/j.coche.2014.12.001 ↗
35. 10.1038/nbt.261210.1038/nbt.2612 ↗
36. 10.1021/acsnano.5b0318410.1021/acsnano.5b03184 ↗
37. 10.1021/acs.chemrev.7b0019410.1021/acs.chemrev.7b00194 ↗
38. 10.1016/j.cis.2015.01.00710.1016/j.cis.2015.01.007 ↗
39. 10.1021/bc400232210.1021/bc4002322 ↗
40. 10.1042/bj2003125310.1042/bj20031253 ↗
41. 10.1038/nrd274210.1038/nrd2742 ↗
42. 10.1016/j.jconrel.2010.11.00410.1016/j.jconrel.2010.11.004 ↗
43. 10.1016/j.biomaterials.2009.02.00910.1016/j.biomaterials.2009.02.009 ↗
44. 10.1021/acs.bioconjchem.8b0073210.1021/acs.bioconjchem.8b00732 ↗
45. 10.1073/pnas.92.16.729710.1073/pnas.92.16.7297 ↗
46. 10.1016/S0006-2952(98)00098-710.1016/S0006-2952(98)00098-7 ↗
47. 10.1038/nrm.2017.13210.1038/nrm.2017.132 ↗
48. 10.1007/s00018-009-0053-z10.1007/s00018-009-0053-z ↗
49. 10.1021/bm400071310.1021/bm4000713 ↗
50. 10.1038/mt.2012.18510.1038/mt.2012.185 ↗
51. 10.1016/B978-0-12-800148-6.00009-210.1016/B978-0-12-800148-6.00009-2 ↗
52. 10.1016/j.canlet.2010.11.00310.1016/j.canlet.2010.11.003 ↗
53. 10.1038/nrc160910.1038/nrc1609 ↗
54. Scher H. I. · Clinical cancer research: an official journal of the American Association for Cancer Research · 1995 · 1 · 545
55. 10.1016/S0959-8049(01)00231-310.1016/S0959-8049(01)00231-3 ↗
56. 10.1016/S0959-8049(01)00230-110.1016/S0959-8049(01)00230-1 ↗
57. 10.1038/nnano.2014.8410.1038/nnano.2014.84 ↗
58. 10.1021/acsnano.7b0473410.1021/acsnano.7b04734 ↗
59. 10.1021/nn402738210.1021/nn4027382 ↗
60. 10.1016/j.bbi.2018.02.01310.1016/j.bbi.2018.02.013 ↗